JO
NVO

John Overdeck’s Novo Nordisk NVO Stock Holding History

John Overdeck’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.18M Sell
66,400
-55,100
-45% -$2.37M ﹤0.01% 2566
2026
Q1 		$4.47M Sell
121,500
-10,500
-8% -$498K ﹤0.01% 2073
2025
Q4 		$6.72M Buy
+132,000
New +$6.75M 0.01% 1437
2019
Q4 		– Sell
-8,000
Closed -$207K – 3891
2019
Q3 		$207K Buy
+8,000
New +$202K ﹤0.01% 3174

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

John Overdeck's NVO Position: Q2 2026 in Review

John Overdeck reduced its Novo Nordisk (NVO) stake by 100% in Q2 2026, selling an estimated $269M and leaving 15,800 shares worth $757K. The position accounts for ﹤0.01% of the portfolio, ranked #3831.

John Overdeck first reported a position in NVO in Q2 2013 and has held it in 39 quarters since. The position peaked at $231M in Q1 2026. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • John Overdeck held 15,800 shares of Novo Nordisk worth $757K as of Q2 2026.
  • John Overdeck sold 6,270,701 Novo Nordisk shares in Q2 2026, an estimated $269M.
  • Novo Nordisk made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #3831 holding.
  • John Overdeck first reported a position in Novo Nordisk in Q2 2013 and has held it in 39 quarters since.
  • John Overdeck's Novo Nordisk position peaked at $231M in Q1 2026.
  • 1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.